CompletedPhase 1

Is Obstructive Sleep Apnea Important in the Development of Alzheimer's Disease?

United States182 participantsStarted 2021-10-08

Plain-language summary

Obstructive sleep apnea (OSA) is common in older adults and has recently been implicated in pathogenesis of Alzheimer's disease (AD). Research has shown that sleep disruptions have caused memory impairment. Sleep apnea is a form of sleep disruption. We would like to examine how obstructive sleep apnea may contribute to the progression of Alzheimer's disease.

Who can participate

Age range65 Years – 85 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age 65-85 years
✓. Gender: Men or Women
✓. MOCA \> 26
✓. Independently living and able to drive
✓. OSA (AHI ≥ 15/h) or no OSA
✓. Subjects must consent to waiving their right to obtain their PHS score (since the score is not yet actionable and could lead to social stress and ethical dilemmas)

Exclusion criteria

✕. Currently smoking
✕. History of COPD or asthma
✕. Heart Failure Class III or IV, unstable cardiovascular disease, or uncontrolled hypertension
✕. Neuromuscular Disease
✕. Drowsy Driving (ESS \> 18/24)
✕. Inability to complete study procedures, such as questionnaire that are only available/validated in English
✕. Lack of decisional capacity to provide informed consent
✕. Participants in whom magnetic resonance imaging Magnetic Resonance Imaging \[MRI\] is contraindicated including, but not limited to, those with a pacemaker, presence of metallic fragments near the eyes or spinal cord, or cochlear implant

What they're measuring

Apnea Hypopnea Index - Crossover

Timeframe: Over 8 hours on each of the two crossover treatment nights

Loop Gain (LG) - Crossover

Timeframe: Over 8 hours on each of the two crossover treatment nights

Neuroimaging - BRAAK12 tauPET

Timeframe: Two 1-hour long scans

Trial details

NCT IDNCT05094271

SponsorUniversity of California, San Diego

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-06-12

Results submitted2025-07-08

View on ClinicalTrials.gov More OSA trials